Last reviewed · How we verify
Minoxidil 5 %
Minoxidil 5% is a marketed topical solution primarily indicated for hair and beard regrowth, developed by Mohammed Abd El Mawgoud Amer. The key composition patent expires in 2028, providing a period of market exclusivity and potential revenue protection. The primary risk is the lack of reported key trial results and revenue data, which may limit investor confidence and market valuation.
At a glance
| Generic name | Minoxidil 5 % |
|---|---|
| Also known as | Local Scalp Injection |
| Sponsor | Mohammed Abd El Mawgoud Amer |
| Drug class | Arteriolar Vasodilator [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Hair and beard regrowth
Common side effects
Key clinical trials
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Topical Methotrexate vs Minoxidil for Localized Alopecia Areata (PHASE4)
- Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia (PHASE3)
- Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE2)
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia (NA)
- Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia (PHASE2)
- Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia (PHASE3)
- A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minoxidil 5 % CI brief — competitive landscape report
- Minoxidil 5 % updates RSS · CI watch RSS
- Mohammed Abd El Mawgoud Amer portfolio CI